

Accepted Manuscript

Title: SURFACE PLASMON RESONANCE IMAGING FOR AFFINITY-BASED BIOSENSORS

Authors: Simona Scarano, Marco Mascini, Anthony P.F. Turner, Maria Minunni




PII: S0956-5663(09)00463-1
DOI: doi:10.1016/j.bios.2009.08.039
Reference: BIOS 3445

To appear in: *Biosensors and Bioelectronics*

Received date: 11-6-2009
Revised date: 15-7-2009
Accepted date: 26-8-2009

Please cite this article as: Scarano, S., Mascini, M., Turner, A.P.F., Minunni, M., SURFACE PLASMON RESONANCE IMAGING FOR AFFINITY-BASED BIOSENSORS, *Biosensors and Bioelectronics* (2008), doi:10.1016/j.bios.2009.08.039

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.






Fig. 3






Fig. 4



Script


Fig. 5



D'Agata, 2008

Fang, 2006

Fig. 6






Fig. 7

1 SURFACE PLASMON RESONANCE IMAGING FOR AFFINITY-BASED
2 BIOSENSORS

3 Simona Scarano*⁺, Marco Mascini*, Anthony P F Turner⁺ and Maria Minunni*

4 *Dipartimento di Chimica, Università degli Studi di Firenze-Polo Scientifico.

5 Via della Lastruccia n° 3, Sesto F.no (FI), Italy; ⁺Cranfield Health, Cranfield University,

6 Cranfield, Bedfordshire MK430AL, UK

7 Corresponding author: maria.minunni@unifi.it

8 Phone: ++39-055-4573314

9 Fax: ++39-055-4573384

10
11 SPR imaging (SPRi) is at the forefront of optical label-free and real-time detection. It offers the
12 possibility of monitoring hundreds of biological interactions simultaneously and from the
13 binding profiles, allows the estimation of the kinetic parameters of the interactions between the
14 immobilised probes and the ligands in solution. We review the current state of development of
15 SPRi technology and its application. Commercially available SPRi instruments are covered.
16 Attention is also given to surface chemistries for biochip functionalisation and suitable
17 approaches to improve sensitivity.

18
19 Keywords: surface plasmon resonance imaging, SPRi, affinity sensing, immobilisation
20 chemistry, signal amplification immunosensor, aptasensor, optical sensor

21

1 Introduction

2 Following its commercial launch in 1990, Surface Plasmon Resonance (SPR) sensing has
3 emerged as a key research tool for pharmaceutical development, food quality control,
4 environmental monitoring and clinical analyses (Homola, 2008). An increasing number of
5 reviews (Fan, 2008; Homola, 2008; Visser, 2008; Jason-Moller, 2006; Pattnaik, 2005), and
6 books (Schasfoort and Tudos, 2008; Homola, 2006) dealing with the fundamentals and
7 applications of SPR-based sensing have been published over the last decade. One of the most
8 important advances in the field is the SPR imaging (SPRi), also called “SPR microscopy”,
9 which couples the sensitivity of scanning angle SPR measurements with the spatial capabilities
10 of imaging. SPRi represents a promising and highly versatile affinity sensing platform suitable
11 for an array format. SPRi has been reported for a variety of affinity systems, including
12 DNA/DNA (Hayashi *et al.*, 2008; Piliarik, 2008; Lecaruyer *et al.*, 2006; Nelson, 2001),
13 RNA/DNA (Li *et al.*, 2006; Nelson, 2002), DNA-binding protein (Jeong *et al.*, 2008;
14 Bouffartigues *et al.*, 2007; Wegner *et al.*, 2003), RNA aptamers/protein (Garcia *et al.*, 2008; Li
15 *et al.*, 2007; Li *et al.* 2006), antibody-antigen (Ladd *et al.*, 2008; Liu *et al.*, 2008; Rebe Raz *et*
16 *al.*, 2008; Wong *et al.*, 2008; Yuk *et al.*, 2006) and carbohydrate/protein (Grant *et al.*, 2008;
17 Mercey *et al.*, 2008; Wakao *et al.*, 2008; Smith *et al.*, 2003). SPRi technology enables affinity
18 interactions to be monitored in real-time and without the use of any label, as in classical SPR
19 sensing, but by using a CCD camera for signal detection both sensorgrams (*i.e.* resonance signal
20 *vs.* time) and images of the chip can be recorded allowing simultaneous analysis of many
21 interactions (up to hundreds).

22
23 This review describes SPRi technology and its applications. Commercially available SPRi
24 instrumentation is included with a focus on some key technical features such as the fluidic

1 system, temperature control, cell and biochip design. Attention is also given to surface chemistry
2 for biochip functionalisation and suitable approaches to improve sensitivity.

3
4 Traditional SPR *cf.* imaging SPR: features and breakthroughs
5 SPR transduction belongs to the class of refractometric sensing devices, which use evanescent
6 waves to investigate surface phenomena. Changes in refractive index at the sensing surfaces due
7 to analyte binding influence the resonant angle and this shift is used to generate a real-time
8 signal. Thus labelling is not required. Commercial SPR instruments are available from numerous
9 suppliers (Homola, 2008), the most frequently reported being the Biacore™ system (GE
10 Healthcare). SPR platforms can be classified according to three modulation approaches: angular,
11 wavelength and intensity (Homola, 2006).

12
13 In contrast to scanning angle SPR and scanning wavelength SPR (traditionally termed “SPR
14 spectroscopy”), SPRi systems are generally based on intensity modulation, measuring the
15 reflectivity of monochromatic incident p-polarised light at a fixed angle. The polariser permits
16 measurements both with p-polarised and s-polarised light, but the latter is used only as reference
17 signal to improve the image contrast and to eliminate artefacts. In the majority of cases, SPRi
18 instruments use a high refractive index prism in the Kretschmann configuration (Kretschmann
19 and Reather, 1968). An alternative is the use of grating couplers (Wassaf *et al.*, 2006). The
20 sensing surface of the prism is coated with a thin metal layer (usually gold or silver,
21 approximately 50 nm in thickness), on which surface plasmons (SPs) are excited by matching
22 SPs and evanescent wave (EW) propagation constants. The resonance conditions depend on the
23 characteristics of the prism, metal and dielectric medium. The best resonance conditions are
24 usually achieved by varying the incident angle of the light on prism. A charge coupled device
25 (CCD) camera collects the reflected light, allowing the visualisation of the whole biochip in real

1 time. If the sensor surface is divided into multiple sensing spots, , *i.e.* microstructured, the device
2 can be used as a multichannel sensor.

3
4 SPRi offers two main advances over conventional SPR: the ability to visualise the entire biochip
5 surface in real time and the chance to monitor up to hundreds of molecular interactions
6 continuously and simultaneously in a multi-array format of molecular probes formed as circular
7 or square spots. It is also possible to control the quality of the spotted array by viewing the
8 surface image to accurately select the measurement area. These Regions of Interest (ROIs) are
9 selected, for example, according to shape, size, and quality of the spot to enhance experimental
10 results. Direct image control of the surface also helps identify and reduce the ubiquitous problem
11 of non-specific binding by defining spots without receptors and spots on gold, to be used as
12 negative control surfaces (negative control ROIs). The ability to immobilise many receptors (up
13 to hundreds) on the surface and to monitor the kinetic parameters of biospecific interactions
14 simultaneously in a real-time and label-free microarray format is a tantalising opportunity. Spots
15 (currently from 50 μm^2 up to 1 cm^2) can be created both manually or by automatic spotters.

16
17 **Characteristics of SPR imaging instruments on the market**
18 Many in-house SPRi instruments have been described (Ladd *et al.*, 2008; Ruemmele *et al.*,
19 2008; Chinowsky *et al.*, 2007; Lecaruyer *et al.*, 2006), but a number of commercial SPRi
20 instruments have recently been launched on market by, for example, GWC Technologies
21 (Madison, USA), IBIS Technologies B.V. (Hengelo, The Netherlands), Genoptics Bio
22 Interactions (Orsay, France) and GE Healthcare (Uppsala, Sweden).

23
24 Except for the Biacore™ Flexchip (GE Healthcare), configured as a grating coupler sensor, the
25 Kretschmann configuration is adopted (Fig. 1a). The measurement is carried out by fixing a

1 single working angle that corresponds to the greatest plasmon curves slope of interest and
2 recording the analytical datum as the intensity variation of the reflected light at that angle for
3 each ROI is detected (Fig. 1b). At the same time interactions are displayed as sensorgrams (Fig.
4 1c). Only the IBIS iSPR instrument operates in scanning angle mode; it directly records the so-
5 called “SPR dip” angle shifts linked to analyte binding. The main difference between these two
6 optical assets relies on the dynamic range of the recorded variable (angle shift or reflectivity
7 change) *vs.* refractive index change (and, consequently, *vs.* mass density change). In particular,
8 measurements conducted in fixed angle mode limit the linear relationship range between
9 reflectivity and change in mass to the linear portion of the plasmon curve. This range
10 corresponds to approximately 5% variation of reflectivity and about 50 mdeg of the SPR dip
11 (Nelson *et al.*, 2001).

12
13 Performance comparisons have been reported (Beusink *et al.*, 2008; Rebe Raz *et al.*, 2008;
14 Lokate *et al.*, 2007). Beusink, *et al.* (2008), using the IBIS iSPR, developed a 24-spot biosensor
15 by immobilising both a short peptide (2.4 kDa) and IgG (150 kDa), modified with biotin, to test
16 the dynamic range, limit of detection and standard deviation of the measurement of anti-biotin
17 mouse IgG. The experiment was conducted in parallel with the SPRimager[®] II system (GWC
18 Technologies) and fluorescence microscopy. The results showed that IBIS iSPR angle scanning
19 mode yielded a 10-fold larger dynamic range compared to the SPRimager[®] II system, allowing
20 the detection of molecules of very different molecular weight simultaneously immobilised on the
21 same sensor chip.

22

23

24 *Liquid handling systems, flow cells and temperature control*

1 The performance of a biosensor is strictly correlated with the control of the hydrodynamic
2 conditions on the sensor surface and, consequently, the liquid handling system plays a crucial
3 role. Flow-through and cuvette systems are available. The first system presents the benefit of
4 well-defined hydrodynamic conditions during measurements without rebinding effects.
5 Microfluidic networks have attracted recent attention and studies to minimise diffusion problems
6 and on analyte mass transport effects have appeared (Kanda *et al.*, 2004; D'Agata *et al.*, 2008).
7 Cuvette systems, allows multiple sample additions. Moreover the cuvette approach reduces
8 sample volume require thus it is very suitable when low volumes are available and/or in case of
9 analyte with low binding constants. Most of SPRi instruments offer both flow through and
10 cuvette systems.

11
12 Another key feature in all SPRi platforms is the flow cell. Early work by Berger *et al.* (1998)
13 reported one- and two-dimensional multichannel immunosensing using a homemade SPRi
14 platform equipped with a four-channel flow cell governed by a four-channel peristaltic pump.
15 Initially, the cell was placed in contact with the biochip and antibody was coated onto its surface
16 by flowing through the channels. The four-channel cell was then turned 90°, thus creating 16
17 independent sensing areas of $\sim 1 \text{ mm}^2$, and an equal number of antibody/antigen signals on a
18 single biochip surface. This multichannel approach has been recently applied to commercial
19 available instrumentation (ProteOn™ XPR36, Bio-Rad Laboratories, CA, USA) based on
20 traditional SPR transduction. At present, the flow cell is designed to let the same analyte solution
21 interact with an array of different probes, minimising the high variability exhibited by
22 multichannel systems. The internal volumes of most flow cell range from few up to hundreds of
23 nanoliters and only slight differences in shape can be found between the different instruments.
24 The SPRimager®II system (GWC Technologies) can be equipped with flow cells of 24 and 12
25 μL internal volume and measurements can be achieved both in stop-flow and recirculation mode.

1 IBIS Technologies supplies the iSPR instrument with standard flow cells (30 μ L) and cuvettes
2 (100 μ L) and the minimum sample volume is 50 μ L. SPRi-Plex and SPRi-Lab⁺ (Genoptics Bio
3 Interactions) not allow sample recirculation and the internal volume of the equipped cells is
4 about 6 μ L. The minimum volume/injection ranges from about 20 μ L for SPRi-Lab⁺ up to 200
5 μ L for SPRi-Plex model. The Biacore family of instrumentation has also recently launched the
6 Flexchip (GE Healthcare) for up to 400 hundred simultaneous measurements. The minimum
7 required volume is P / D O W K R X J K W K H F H O O Y R O X P H L V R I /
8 for application of the system to molecular biology research, but competitive for proteomic
9 studies.

10 Some commercially available instruments have temperature control. The IBIS-iSPR has high
11 precision temperature control and both the sample deck (with microtitre plate) and sensor can be
12 cooled or heated with 0.01-degree precision ($^{\circ}$ C) facilitating thermodynamic kinetic analyses.
13 SPRi-Plex, from Genoptics' has a Peltier temperature control system between 15 $^{\circ}$ C and 40 $^{\circ}$ C
14 with a 0.1 $^{\circ}$ C precision and a 0.01 $^{\circ}$ C stability. Thermostatic control can be also obtained with the
15 fully automated Flexchip in the range 25 $^{\circ}$ -37 $^{\circ}$ C.

16 To address the lack of temperature control some groups have reported in house developed
17 temperature control from 25 to 70 $^{\circ}$ C (Corne *et al.*, 2008) or temperature scanning to perform
18 melting curves on DNA duplexes for point mutation detection (Fiche *et al.*, 2008).

19
20 **SPRi Biochips**
21 Immobilisation of the molecular probe should be reproducible, retain biological activity and
22 orientate the receptor for optimal binding. Moreover the number and type of probes can vary,
23 depending of the application under study. It is not easy to fulfil all these requirements thus ready
24 to use chips are available from different companies commercialising SPRi instrumentation for

1 not experienced users. Alternatively many groups familiar with biosensors, report about
2 interesting chemical approaches for the SPRi biochips development.

3 The common strategy for realising spots is to isolate small areas of the surface and to surround
4 them by an antifouling environment, thus reducing non-specific SPRi signals from background.
5 An example is the commercial SpotReady™ gold chip (GWC Technologies).

6 Pre-coated chips are also available with different types of chemicals (e.g. Z-terminated amine
7 carboxylic functionalities from IBIS Technologies) suitable for further chemical modifications.

8 Electropolymerisation of pyrrolated-conjugates prepared using pyrrole-NHS, pyrrole-
9 phosphoramidite and pyrrole-hydrazide is also applied for biochip development by Genoptics

10 Behind ready to use biochips, one can develop suitable chemistry for bioreceptor immobilisation.

11

12 Immobilisation methods

13 In SPRi the sensor surface is almost always a thin layer of gold. Most immobilisation techniques
14 involve a first layer of a chemical linker directly bound to the gold, allowing subsequent
15 anchoring of molecules of interest. The main objective is to create a support structure for the
16 receptor that ensures stability under working conditions and access to the analyte, while
17 minimising receptor detachment. The use of a blocking agent prevents non-specific adsorption.

18 A variety of chemical strategies have been reported for SPRi-based sensing.

19 A favoured immobilisation method is the use of a self-assembled monolayer (SAM) on the gold
20 surface, which increases the degrees of freedom of the probe and, consequently, those of binding
21 target molecules. SAMs can be formed by thiol-modified biomolecules, *e.g.* DNA (Manera *et al.*,
22 2008) and RNA (Piliarik *et al.*, 2008) sequences, directly attached to the gold surface by
23 exploiting its high affinity with thiol groups (Fig. 2). Alternatively, the receptor can be
24 covalently attached via alkanethiols and alkoxylenes containing Z-terminated amine (Lee *et al.*,
25 2005; Smith *et al.*, 2003), hydroxylic (Mannelli *et al.*, 2007) or carboxylic (Liu *et al.*, 2008; Park

1 *et al.*, 2008; Mannelli *et al.*, 2007) functional groups (Fig. 2). Probe immobilisation to
2 polyelectrolyte films via electrostatic interactions has also been reported. In particular, 11-
3 mercaptoundecanoic acid (MUA) modified gold surfaces were exposed to a polyelectrolyte film
4 of branched poly(ethylenimine) (PEI) (Mannelli *et al.* 2007), in which the amino groups bind the
5 carboxylic end of the MUA electrostatically. The high-density extravidin layer then strongly
6 binds the biotinylated probes (Bassil *et al.*, 2003) via the extravidin–biotin complex (Fig. 2).

7
8 Alternatively, SAMs were formed by mixtures of 7 parts to 3 1-mercapto-11-
9 undecyltetra(ethylene glycol) (OEG) and carboxylic acid-capped hexa(ethylene
10 glycol)undecanethiol (COOH-OEG). Carboxylic groups of COOH-OEG were then activated
11 with N-hydroxysuccinimide (NHS) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
12 hydrochlorid (EDAC) for antibody immobilisation by amino-coupling (Ladd *et al.*, 2008) (Fig.
13 2). Finally, a SAM layer comprising DNA sequences and OEG was created on a gold surface for
14 the simultaneous detection of DNA and protein analytes (Ladd 2008a). Thiol-modified single-
15 stranded DNA sequences were spotted onto gold-coated glass substrates, which were then
16 immersed in an OEG-terminated thiol solution. This last step created a protein-resistant surface
17 background and improved the orientation of the DNA molecules. Antibodies conjugated to
18 complementary single-stranded DNA sequences were immobilised on the surface through DNA
19 hybridisation. By converting only part of the DNA array into a protein array, both nucleic acid
20 and proteins could be immobilised.

21
22 Corn and co-workers have developed immobilisation protocols over the last decade for
23 immobilising nucleic acids (DNA and RNA probes, RNA aptamers), peptides, proteins and
24 carbohydrates. Their fabrication procedures uses a reversible protecting groups to manipulate
25 surface properties during array construction (Wegner *et al.*, 2004; Brockman *et al.*, 2000) to

1 spatially confine aqueous solutions. A monolayer of 11-mercaptoundecylamine (MUAM) is
2 adsorbed via self-assembly onto an evaporated gold thin film, which can then be reversibly
3 protected using organic protecting molecules. In one of the most used methods, a reversible
4 amine, 9-fluorenylmethoxycarbonyl (Fmoc), acts as protecting group to form a hydrophobic
5 surface. By ultraviolet (UV) photo-patterning squares of bare gold are then obtained and further
6 exposed to MUAM. Thiol-modified DNA is covalently attached to the MUAM squares using a
7 bifunctional linker, *i.e.* the sulfosuccinimidyl 4-(*N*-maleimidomethyl)cyclohexane-1-carboxylate
8 (SSMCC). The linker contains a N-hydroxysulfosuccinimide ester (NHSS) functionality
9 (reactive toward amines) and a maleimide functionality (reactive toward thiols) (Smith *et al.*,
10 2003). Alternatively single-stranded, thiol-modified DNA is immobilised using SATP (*N*-
11 Succinimidyl S-acetyl-thiopropionate). Deprotection of SH group on the surface is achieved
12 using Dithiothreitol (DTT), a small redox molecule, leaving the sulfhydryl to react with
13 dipyridyl disulphide (DPDS) to create a pyridyl disulfide surface. Finally a thiolated molecular
14 probe can be bound to the surface by an exchange reaction between the pyridyl sulphide and the
15 thiol group of the probe (Fig. 2).

16
17 The formation of a hydrogel film composed of carboxymethyl dextran covalently linked to the
18 gold surface with the SAM layer is a widely used method to immobilise the probe for SPR and
19 piezoelectric sensing (Tombelli *et al.*, 2005; Löfås *et al.*, 1995; Löfås and Johnson, 1990). By
20 activating the caboxymethyl groups, amino-coupling of protein receptors can be achieved. This
21 approach has been adopted in SPRi for peptide and antibody immobilisation (Beusink *et al.*,
22 2008). Alternatively, biotinylated molecular probes can be attached via avidin/streptavidin
23 binding previously immobilised using the aforementioned dextran chemistry (Mannelli *et al.*,
24 2007) (Fig. 2).

25

1 One limitation of amino-coupling is the lack of control of receptor orientation, since coupling
2 can occur randomly with any aminic group on the side-chains. In the case of antibody arrays this
3 implies a reduction in the biosensor sensitivity and reproducibility. A number of papers deal with
4 new immobilisation procedures to overcome these drawbacks. For antibody arrays, genetically
5 engineered *Streptococcus* bacteria were employed to produce protein G with cysteine residues at
6 the N-terminus allowing orientation (Lee *et al.*, 2007) (Fig. 3). Cysteine residues can be
7 genetically introduced into the specific site of the target protein, and this modified protein forms
8 a properly oriented protein layer through the thiol group adsorption on the gold surface in either
9 thiolate or disulfide form (Kallwass *et al.*, 1993) for biosensor development (Di Felice and
10 Selloni, 2004; Persson *et al.*, 1990). Protein G was used as an affinity receptor for antibody
11 immobilisation affording better orientation of immobilised antibodies as well as a higher SPRi
12 sensitivity against antigen targets. Recently, a modified antibody immobilisation introducing a
13 novel linker, protein G-DNA conjugate, was reported (Jung *et al.*, 2007) that possesses the
14 strengths of both protein G and DNA-directed immobilisation. DNA-directed immobilisation
15 allows spatial assembly of target proteins on DNA-functionalised assay surfaces (Schroeder *et*
16 *al.*, 2009), resulting in robust and stable chemical linkers (Fig. 3) for SPR transduction and
17 offering possibilities for SPRi.

18
19 Another immobilisation method involves polymeric species, mainly based on polypyrrole
20 (Cosnier *et al.*, 2003). Livache and colleagues developed an electropolymerisation technique for
21 SPRi using the electrochemically directed copolymerization of pyrrole and oligonucleotides
22 bearing on their 5' end a pyrrole moiety (Bidan *et al.*, 2000) (Fig. 3). The resulting polymer film
23 on the electrode consists of pyrrole chains bearing covalently linked oligonucleotides (a mixed
24 solution of DNA-pyrrole and pyrrole monomers). Initially developed for the construction of
25 DNA chips, the polypyrrole approach has been then extended to other biochemical compounds,

1 mainly proteins (Grosjean *et al.*, 2005) and oligosaccharides (Mercey *et al.*, 2008). The
2 electropolymerisation reaction is based on an electrochemical process allowing a very fast
3 coupling of the probe directly to a gold working electrode, without the need for further chemical
4 linkers.

5
6 Very recently, in order to synthesise oligonucleotide probes *in situ*, a quite different approach
7 has been proposed by Lockett *et al.* (2008), to create a more resistant surface to oxidation and
8 photodegradation. A lamellar structure in which a thin layer of amorphous carbon was deposited
9 onto the gold thin film was developed. Carbon-based surfaces can be readily modified with
10 biomolecules *i.e.* by attachment of alkene-containing molecules by UV light-mediated formation
11 of carbon-carbon bonds. The surface was further functionalised with 9-decene-1-ol leading to
12 hydroxylic terminated surface, which was modified via photolithographic chemical methods,
13 using oligonucleotide bases modified with a photolabile 3'-nitrophenylpropyloxycarbonyl-
14 (NPPOC-) protecting group (Fig. 3).

15
16 The best choice of surface attachment chemistry is not yet clearly established mainly because it
17 depends on many factors such as the biomolecule type to be immobilised, the sample medium
18 and the detection method.

19 20 4. Strategies for signal amplification

21 Typical DNA samples contain attomolar or femtomolar concentrations, which are well below the
22 nanomolar detection limit SPRi. Hence, sample enrichment (PCR amplification), has been
23 generally applied (Goodrich *et al.*, 2004a) although in few cases DNA sequences have been
24 detected directly *e.g.* extracted from plant using piezoelectric sensing (Minunni *et al.*, 2005),

1 from human lymphocytes by traditional SPR (Minunni *et al.*, 2007) and from bacteria by SPRi
2 (Nelson *et al.*, 2002).

3
4 In order to increase the sensitivity of SPRi, signal amplification has been developed by: a)
5 increasing the SPR output signal through mass or enzymatic processes at the receptor/analyte
6 adduct; b) increasing of the intensity of the evanescent field by structuring the chip surface. Mass
7 enhancement is achieved by addition of molecules which selectively interact with the receptor-
8 ligand complex formed at the surface. It was first applied to SPRi for DNA detection by Jordan
9 *et al.* (1997), who combined the hybridisation step with subsequent biotin/streptavidin binding
10 (Fig. 4). Both mass and enzyme-based enhancements have been applied to the detection of the
11 signalling protein Vascular Endothelial Growth Factor (VEGF) at 1 pM physiological
12 concentration (Li *et al.* 2007). A VEGF-specific aptamer bound the protein, followed by the
13 addition of biotinylated anti-VEGF antibody (sandwich-type assay). The SPRi signal was further
14 amplified using an anti-biotin conjugated horseradish peroxidase (HRP) which, in presence of an
15 HRP substrate such as 3,3',5,5'-tetramethylbenzidine (TMB), created a localised dark-blue
16 precipitation reaction with SPRi signal enhancement (Fig. 4).

17
18 DNA-linked gold nanoparticles have also been used for SPRi signal amplification with
19 immobilised peptide nucleic acid (PNA) sequences to detect point mutations. The target
20 sequences hybridise the PNA probe on the chip surface and amplification is achieved by DNA-
21 modified nanoparticles binding to a different region of the target sequence (Fig. 5). Selective and
22 ultrasensitive (1 fM) mismatch recognition was successfully achieved (D'Agata *et al.*, 2008).
23 Fang *et al.* (2006) reported a similar approach using a polyadenine (polyA) tail, synthesised *in*
24 *situ*, added to the target sequence to bind its complementary LNA (Locked Nucleic Acid) probe.

1 PolyT-modified nanoparticles, binding the polyA tails were then added to form a ternary surface
2 complex. The reported detection limit for 19-23 mers miRNA was of 10 fM (Fig. 5).

3
4 A combination of surface hybridisation, surface ligation and nanoparticle amplification has been
5 applied to point mutation detection (Li *et al.*, 2006a) by exploiting signal magnification obtained
6 only when DNA sequences were fully matched, *i.e.* not containing Single Nucleotide
7 Polymorphisms (SNPs). Arrays of two sets of probes, differing only in the last nucleotide at their
8 3' ends specific to the SNP (Fig. 6, grey bars showed in step 1) were exposed to a target solution
9 (blue bars) containing a second DNA sequence ("ligation probe DNA", orange bar) and Taq
10 DNA ligase enzyme. Duplexes were formed (Fig. 6; Step 1) where Taq DNA ligase could only
11 extend the probe sequences with the ligation probe if the receptor did not contain the SNP. After
12 ligation, treatment with 8 M urea selectively denatured the adducts containing the SNP.
13 Finally, nanoparticles modified with oligonucleotides complementary to the ligation probe DNA
14 were added. The SPRi signal, recorded only where the ligation occurred, revealed if the target
15 DNA contained the SNP (Fig. 6, step 2). The detection limit was 1 pM using 36 mer
16 oligonucleotides and the system was applied to point mutation detection in the BRCA1 gene,
17 which is a breast cancer diagnostic.

18
19 A novel approach for DNA detection used RNase H in conjunction with RNA microarrays
20 (Goodrich *et al.*, 2004 & 2004a) (Fig. 7). The exonuclease selectively destroys RNA sequences
21 only in RNA-DNA heteroduplexes, releasing the DNA back to into solution. A single-stranded
22 RNA (ssRNA) microarray was exposed to a solution containing both complementary DNA and
23 RNase H (Fig. 7; Step 1). The DNA binds its RNA complement on the surface (Fig. 7, step 2).
24 RNase H then binds to this heteroduplex, selectively hydrolysing the RNA probe (Fig. 7, step 3),
25 and then releasing the DNA complement back into solution (Fig. 7, step 4). The released DNA

1 molecule is then free to bind to another RNA probe on the surface, so that a single DNA
2 molecule can initiate the destruction of many surface-bound RNA probes (Fig. 7, step 5). With
3 sufficient time, all of the RNA probe molecules are removed from the surface resulting in a
4 decrease of the SPRi signal (Fig. 7, step 6). Hence, one sequence could in theory prime the
5 enzymatic catalysis and lead to the destruction of the heteroduplexes on the surface to generate
6 an observable SPRi signal. In practice, the detection limit was 1000 times improved allowing
7 DNA detection down to 1fM.

8
9 Other forms of SPRi amplification focus on surface engineering. Long-Range Surface Plasmons
10 (LRSPs) are surface electromagnetic waves that can be created on thin metallic films imbedded
11 between two identical dielectric media. LRSPs have been known for almost thirty years (Quail *et*
12 *al.*, 1983), but have only recently been used for the characterisation of thin-films or for
13 bioaffinity measurements. Wark *et al.* (2005) used SPRi to demonstrate the suitability of LRSPs
14 for molecular detection and for thin-film sensing in general. A micrometric layer of a
15 commercially available inert, optically transparent material (Cytop, CTL-809M.) with a
16 refractive index very close to water was deposited on a prism coupler surface. A gold layer was
17 then vapour-deposited onto the prism surface and chemically modified for probe immobilisation.
18 Results obtained showed that it is possible to enhance the SPRi output signal by about 20% due
19 to the narrow LRSP resonance curve.

20
21 Improvement in sensitivity can also be obtained by “nanostructuring” the SPR interface. Lisboa
22 *et al.* (2008) patterned the gold surface of SPRi chips using two organothiols, *i.e.* thiolated
23 polyethylene oxide (PEO), which is unsusceptible to protein and cell adhesion, and
24 mercaptohexadecanoic acid (MHD) with a carboxylic group suitable for coupling to the amino
25 group of a bioreceptor. The surface was modified with active “nanospots” for subsequent probe

1 immobilisation, surrounded by an inert PEO surface. The nanoarrayed surface produced five
2 times the sensitivity for the Human IgG/anti Human IgG immunoreaction compared to the
3 standard uniform immobilisation.

4
5 **5. SPR imaging transduction in affinity sensing**
6 Shortly after its introduction by Yeatman and Ash (1987) SPRi was used in a biomolecular
7 application for the imaging of phospholipid monolayer films (Hickel *et al.*, 1989). Since then,
8 SPRi has also been used for surface morphological investigations of many systems, including
9 self-assembled monolayer films (Evans and Flynn, 1995), mono- and multilayer films prepared
10 by Langmuir-Blodgett techniques (Duschl *et al.*, 1996) and multilayer films by alternating
11 polyelectrolyte deposition (Nelson *et al.*, 1999). More recently, SPRi was applied in array-type
12 configurations for studying molecular recognitions between nucleic acids, nucleic acids and
13 protein, immunoreactions and interaction with carbohydrates.

14 15 **5.1 Nucleic acid arrays for SPRi**

16 Over the past two decades, Corn's research group has optimised immobilisation chemistries for
17 microarray development for SPRi, mainly focusing on DNA and RNA sequences. SPRi has been
18 applied to hybridisation-based sensing for many applications, including bacterial genotyping,
19 SNP identification and studying DNA repair. Nucleic acid arrays are also providing innovative
20 tools for the survey of biomolecular interactions between DNA and RNA sequences and binding
21 proteins (Jeong *et al.*, 2008; Bouffartigues *et al.*, 2007; Wegner *et al.*, 2003).

22 Opening up the field of genotyping for environmental and clinical applications, detection of 16S
23 ribosomal RNA from *E. coli* with short, unlabelled DNA and RNA sequences by SPRi was
24 successfully demonstrated (Nelson *et al.*, 2002; Nelson *et al.*, 2001). Other research groups

1 (Manera *et al.*, 2008a; Piliarik *et al.*, 2008, Hottin *et al.*, 2007) have obtained promising results
2 for bacterial pathogens, but data are still scarce for real matrices.

3
4 Specific RNA arrays for SPRi have been designed to demonstrate the specificity and affinity
5 between synthetic aminoglycoside antibiotics (kanamycins) and RNA sequences (Nishimura *et*
6 *al.*, 2005) to elucidate aminoglycoside-RNA recognition in order to overcome resistance and side
7 effects of antibiotics. It was shown that kanamycins have non-specific, multiple interactions with
8 RNA hairpins and that the binding strength is not always proportional to the antimicrobial
9 activity.

10
11 Due to its capability to discriminate between highly similar nucleotide sequences, SPRi has
12 recently gained the attention of researchers investigating SNPs (Fiche *et al.*, 2008; Hayashi *et al.*,
13 2008) and gene mutation (Lecaruyer *et al.*, 2006). SPRi applicability for point mutations rapid
14 screening, was demonstrated by Livache's, using in-house apparatus, performing temperature
15 scans. DNA probe sequences carrying different point mutations were immobilised and
16 distinguished perfectly matched duplexes from mismatched ones by virtue of their different
17 melting temperature over ten temperature scans (Fiche *et al.*, 2008). The results showed that
18 imaging coupled with temperature scans can be an efficient and low-cost tool for point mutation
19 detection on DNA chips.

20
21 Some crucial enzyme activities have also been investigated using immobilised DNA sequences
22 such as the binding and catalytic properties of DNA N-glycosylase towards damaged DNA sites
23 (Corne *et al.*, 2008; 2008a). DNA N-glycosylases are enzymes involved in Base Excision Repair
24 (BER), which is the major mechanism for correction of damaged nucleobases. A decrease of
25 BER activity is correlated to carcinogenesis and aging and the study of biological interactions

1 between damaged DNA and repair enzymes have a crucial role in the search for new DNA repair
2 inhibitors and the understanding of DNA repair mechanisms (Baute *et al.*, 2008).

3
4 The importance of microRNAs (miRNAs) in gene expression and regulation, as well as in cell
5 function is well established (Williams *et al.*, 2008) and the synthesis of miRNA has been
6 investigated by SPRi (Wark *et al.*, 2008; Fang *et al.*, 2006) for possible clinical diagnostic
7 applications. Promising high-quality miRNA profiling for simple, rapid and multiplexed
8 analyses is emerging. Another class of nucleic acid sequences, aptamers, represents a
9 competitive tool for proteomic research such as protein biomarker discovery (Tombelli *et al.*,
10 2007). Aptamers are a promising alternative to antibody microarrays for clinical analysis and
11 SPRi aptasensing has already been reported for the detection of human Immunoglobulin E
12 (Wang *et al.*, 2007), human factor IXa (Li *et al.*, 2006) and vascular endothelial growth factor
13 (Li *et al.*, 2007).

14
15 **5.2 Protein and short peptide arrays for SPRi**
16 Increasing interest in the analysis of peptides and proteins using array formats with surface-
17 sensitive optical techniques like SPRi is prompted by the chance to detect the biomolecular
18 interactions without labelling, which may adversely affect molecular structures. Jung *et al.*
19 (2005) recently developed protein microarrays for high-throughput SPRi measurements and
20 tested a SPRi platform for protein–protein interactions (Ro *et al.*, 2005; 2006). The approach
21 facilitated the study of protein-protein interactions where multiple proteins are involved and
22 demonstrated high-throughput monitoring of affinity-tagged proteins in expression and
23 purification processes (Ro *et al.*, 2005). Moreover, they chose the Human Papilloma Virus E6
24 protein with its binding proteins, the ligase E6AP and the tumor suppressor p53, as a model
25 study to investigate the triple protein interaction (E6/E6AP/p53) that takes place during the viral

1 infection (Ro *et al.*, 2006). The complex formation induces a degradation of p53 and,
 2 consequently causes the transformation of normal cells into malignant cells and work in this area
 3 supports the development of new anticancer drugs against HPV-related cervical cancer. More
 4 recently, they also reported the study of caspase-3 activation by SPRi (Park *et al.*, 2008).
 5 Caspase-3 is an intracellular cysteine protease and plays a crucial role in the apoptotic cell
 6 process. Its activation is commonly used as a biomarker for assessment and understanding of
 7 apoptosis, and is conventionally detected using an anti-FLDO ÀXRURJHQLF VXE V W U
 8 blotting. The new method measured a fluorescence signal adapted to SPRi. A chimeric caspase-3
 9 substrate (GST:DEVD:EGFP) composed of glutathione S transferase (GST) and enhanced green
 10 ÀXRUVFHQW SURWHLQ (*)3 ZLWK D VSHFLDOLVHG O L Q M
 11 sequence (DEVD) was developed. Utilizing this caspase-3-dependent proteolytic reporter, they
 12 successfully monitored the proteolytic activity of caspase-3. These results confirm that SPRi
 13 offers new ways to study protein mechanisms without labelling.

14
 15 Short peptides play an important role in identifying important residues in protein-protein
 16 recognition processes and in the understanding of peptide-DNA interactions and enzymatic
 17 modification of peptides. Katayama's group has recently developed SPRi to explore peptide
 18 probes as kinase substrates (Mori *et al.*, 2008; Inamori *et al.*, 2005). The synthesis of drugs
 19 modulating the activities of particular protein kinases has become a prime focus of the
 20 pharmaceutical and biotechnology industry, thus development of high-throughput screening
 21 formats for these enzymes is of crucial interest. Mori and colleagues proposed a novel detection
 22 system for on-chip phosphorylation of peptide probes and a zinc(II) chelate compound, working
 23 independently of the amino acid residues on the array, using a single-probe complex, differing
 24 from in solution conventional methods (Sola-Penna *et al.*, 2002; Ross *et al.*, 2002).

25

1 SPRi immunosensor based on antibodies arrays, have been also reported. Work dealt with
2 antibodies orientation for enhancing sensor performance (Jung *et al.*, 2007; 2008; Lee *et al.*,
3 2007) and assays for candidate cancer biomarkers. Anti-activated cell adhesion molecule/CD
4 166 (anti ALCAM) and anti transgelin-2 (anti TAGLN2) antibodies were employed for the
5 identification and quantitation of the relative ALCAM and TAGLN2 antigens (Ladd *et al.*, 2008)
6 immobilised in array format. The detection limits in buffer were in the ppb range for both
7 targets, which is compatible with physiological levels in human serum (typically 10 to 100 ppb),
8 although high non-specific signals were found in spiked 10-fold diluted commercial serum
9 samples. Better results can be expected by improving the surface chemistry to reduce matrix
10 effects.

11

12 5.3 Carbohydrate microarrays for SPRi

13 As mentioned above, carbohydrates are interesting candidates for array format analysis, but
14 publications are sparse due to the lack of reliable methods of fabrication. Smith *et al.* (2003)
15 reported the fabrication of mannose and galactose carbohydrate arrays on gold films using poly-
16 (dimethylsiloxane) (PDMS) microchannels and their use in SPRi to monitor the binding of the
17 lectins jacalin and concanavalin A (ConA). They quantified the strength of lectin-carbohydrate
18 interactions by determining the adsorption coefficients and the solution dissociation constants for
19 the lectins ConA and jacalin, highlighting the potential of SPRi for weak protein-carbohydrate
20 interaction studies. Karamanska *et al.* (2008) recently adopted a similar approach and their data
21 confirms the feasibility of a label-free and selective lectin-glycan recognition using SPRi.

22

23 An interesting biotechnological application for screening phage display has been described by
24 Weiss' and Corn's groups (Lambooy *et al.*, 2008) using a poly-L-lysine-modified surface created
25 by the photopatterning of adsorbed 11-mercaptoundecanoic acid. The peptides Lys_n (n=16 to 24)

1 emerged as optimal for wrapping the phage. The patterned surface was exposed to a solution of
2 phage in water that was allowed to adsorb electrostatically onto the surfaces. Lys_n also provided
3 effective wrappers for RNA binding in assays against the RNA-binding protein HIV-1 viral
4 infectivity factor Vif. The oligolysine peptides blocked non-specific binding to allow successful
5 selection and screening of the targets.

6

7 6. Concluding remarks

8 SPRi represents the forefront of label-free and real-time optical detection of many (up to
9 hundreds) biological interactions simultaneously, furnishing binding profiles for the estimation
10 of the kinetic parameters of the different interactions between immobilised probes and ligands in
11 solution. Most of the immobilisation protocols originate from research on traditional SPR-based
12 biosensing. Applications addressed by SPRi vary from protein-protein interactions, hybridisation
13 reactions with DNA, RNA or *in vitro* selected nucleic acids such aptamers with the specific
14 ligands or carbohydrate–lectin interactions. In order to improve sensitivity, signal amplification
15 can be achieved by nanopatterning the sensing surface or by addition of enzyme or nanoparticle-
16 labelled reagents, facilitating detection limits down to 1 fM of DNA for point mutation analysis.
17 Given the wide applicability of this emerging technology, some commercial instrumentation has
18 appeared on the market with dedicated ready-to-use chips. Interest in SPRi technology is rising
19 quickly and we can expect that it will become important in areas ranging from environmental
20 and food analysis to clinical diagnostics.

21

22 Acknowledgments

23 Maria Minunni, Coordinator of the project: "Affinity-Based Biosensing (ABB) for gene doping
24 detection: an integrated approach" would like to thanks World Anti-Doping Agency (WADA)
25 for financial support.

26

1 Bibliography

- 2 Bassil, N., Maillart, E., Canva, M., Lévy, Y., Millot, M.-C., Pissard, S., Narwa, R. & Goossens,
3 M. (2003). *Sensors and Actuators B: Chemical*, 131, 633-638.
4
- 5 Baute, J. & Depicker, A. (2008). *Critical Reviews in Biochemistry and Molecular Biology*, 43,
6 239-276.
7
- 8 Berger, C.E.H., Beumer, T.A.M., Kooyman, R.P.H. & Greve, J. (1998). *Analytical Chemistry*,
9 70, 7703 -7706.
10
- 11 Beusink, J.B., Lokate, A.M., Besselink, G.A., Pruijn, G.J. & Schasfoort, R.B. (2008).
12 *Biosensors and Bioelectronics*, 23, 839-844.
13
- 14 Bidan, G., Billon, M., Galasso, K., Livache, T., Mathis, G., Roget, A., Torres-Rodriguez, L.M.
15 & Vieil, E. (2000). *Applied Biochemistry and Biotechnology*, 89, 183-193.
16
- 17 Bouffartigues, E., Leh, H., Anger-Leroy, M., Rimsky, S. & Buckle, M. (2007). *Nucleic Acids*
18 *Research*, 35, e39.
19
- 20 Corne, C., Fiche, J.B., Gasparutto, D., Cunin, V., Suraniti, E., Buhot, A., Fuchs, J., Calemczuk,
21 R., Livache, T. & Favier, A. (2008). *Analyst*, 133, 1036-1045.
22
- 23 Corne, C., Fiche, J.B., Cunin, V., Buhot, A., Fuchs, J., Calemczuk, R., Favier, A., Livache, T. &
24 Gasparutto, D. (2008a). *Nucleic Acids Symposium Series*, 249-250.
25
- 26 Cosnier, S. (2003). *Analytical and Bioanalytical Chemistry*, 377, 507-520.
27
- 28 D'Agata, R., Corradini, R., Grasso, G., Marchelli, R. & Spoto, G. (2008). *Chembiochem*, 9,
29 2067-2070.
30
- 31 Di Felice, R. & Selloni, A. (2004). *Journal of Chemical Physics*, 120, 4906-4914.
32
- 33 Duschl, C., Liley, M., Lang, H., Ghandi, A., Zakeeruddin, S.M., Stahlberg, H., Dubochet, J.,
34 Nemetz, A., Knoll, W. & Vogel, H. (1996). *Materials Science & Engineering C-Biomimetic*
35 *Materials Sensors and Systems*, 4, 7-18.
36
- 37 Evans, S.D. & Flynn, T.M. (1995). *Langmuir*, 11, 3811.
38
- 39 Fang, S., Lee, H.J., Wark, A.W. & Corn, R.M. (2006). *Journal of American Chemical Society*,
40 128, 14044-14046.
41
- 42 Fiche, J.B., Fuchs, J., Buhot, A., Calemczuk, R. & Livache, T. (2008). *Analytical Chemistry*, 80,
43 1049-1057.
44
- 45 Garcia, B.H.N. & Goodman, R.M. (2008). *Journal of Virological Methods*, 147, 18-25.
46
- 47 Goodrich, T.T., Lee, H.J. & Corn, R.M. (2004). *Journal of American Chemical Society*, 126,
48 4086-4087.
49

- 1 Goodrich, T.T., Lee, H.J. & Corn, R.M. (2004a). *Analytical Chemistry*, 76, 6173-6178.
2
3 Grant, C.F., Kanda, V., Yu, H., Bundle, D.R. & McDermott, M.T. (2008). *Langmuir*,
4
5 Hayashi, G., Hagihara, M. & Nakatani, K. (2008). *Journal of Biotechnology*, 135, 157-160.
6
7 Hickel, W., Kamp, D. & Knoll, W. (1989). *Nature*, 339, 186.
8
9 Homola, J. (2006) Springer-Verlag Berlin and Heidelberg GmbH & Co. K.
10
11 Homola, J. (2008). *Chemical Reviews*, 108, 462-493.
12
13 Hottin, J., Moreau, J., Roger, G., Spadavecchia, J., Millot, M.C., Goossens, M. & Canva, M.
14 (2007). *Plasmonics*, 2, 201-215.
15
16 Inamori, K., Kyo, M., Nishiya, Y., Inoue, Y., Sonoda, T., Kinoshita, E., Koike, T. & Katayama,
17 Y. (2005). *Analytical Chemistry*, 77, 3979-3985.
18
19 Jason-Moller, L., Murphy, M. & Bruno, J. (2006). *Current Protocols in Protein Science*, Chapter
20 19, Unit 19.13.
21
22 Jeong, E.J., Jeong, Y.S., Park, K., Yi, S.Y., Ahn, J., Chung, S.J., Kim, M. & Chung, B.H. (2008).
23 *Journal of Biotechnology*, 135, 16-21.
24
25 Jung, S.O., Ro, H.S., Kho, B.H., Shin, Y.B., Kim, M.G. & Chung, B.H. (2005). *Proteomics*, 5,
26 4427-4431.
27
28 Jung, Y., Kang, H.J., Lee, J.M., Jung, S.O., Yun, W.S., Chung, S.J. & Chung, B.H. (2008).
29 *Analytical Biochemistry*, 374, 99-105.
30
31 Jung, Y., Lee, J.M., Jung, H. & Chung, B.H. (2007). *Analytical Chemistry*, 79, 6534-6541.
32
33 Kallwass, H.K.W., Parris, W., McFarlane, E.L.A., Gold, M. & Jones, J.B. (1993). *Biotechnology*
34 *Letters*, 15, 29-34.
35
36 Kanda, V. & McDermott, M.T. (2004). *Analytical Chemistry*, 76, 7257-7262.
37
38 Karamanska, R., Clarke, J., Blixt, O., Macrae, J.I., Zhang, J.Q., Crocker, P.R., Laurent, N.,
39 Wright, A., Flitsch, S.L., Russell, D.A. & Field, R.A. (2008). *Glycoconjugate Journal*, 25, 69-74.
40
41 Kretschmann, E. & Raether, H. (1968). *Verlag der Zeitschrift für Naturforschung*, 23, 2135-
42 2136.
43
44 Ladd, J., Taylor, A.D., Piliarik, M., Homola, J. & Jiang, S. (2008a). *Analytical Chemistry*, 80,
45 4231-4236.
46
47 Ladd, J., Taylor, A.D., Piliarik, M., Homola, J. & Jiang, S. (2008). *Analytical and Bioanalytical*
48 *Chemistry*, 393, 1157-1163.
49
50 Lamboy, J.A., Tam, P.Y., Lee, L.S., Jackson, P.J., Avrantinis, S.K., Jin Lee, H., Corn, R.M. &

- 1 Weiss, G.A. (2008). *Chem Bio Chem*, 9, 2846-2852.
2
- 3 Lecaruyer, P., Mannelli, I., Courtois, V., Goossens, M. & Canva, M. (2006). *Analytica Chimica*
4 *Acta*, 573-574, 333-430.
5
- 6 Lee, H.J., Wark, A.W., Li, Y. & Corn, R.M. (2005). *Analytical Chemistry*, 77, 7832-7837.
7
- 8 Lee, J.M., Park, H.K., Jung, Y., Kim, J.K., Jung, S.O. & Chung, B.H. (2007). *Analytical*
9 *Chemistry*, 79, 2680-2687.
10
- 11 Li, Y., Lee, H.J. & Corn, R.M. (2006). *Nucleic Acids Research*, 34, 6416-6424.
12
- 13 Li, Y., Lee, H.J. & Corn, R.M. (2007). *Analytical Chemistry*, 79, 1082-1088.
14
- 15 Li, Y., Wark, A.W., Lee, H.J. & Corn, R.M. (2006a). *Analytical Chemistry*, 78, 3158-3164.
16
- 17 Liu, W., Chen, Y. & Yan, M. (2008). *Analyst*, 133, 1268-1273.
18
- 19 Lockett, M.R., Weibel, S.C., Phillips, M.F., Shortreed, M.R., Sun, B., Corn, R.M., Hamers, R.J.,
20 Cerrina, F. & Smith, L.M. (2008). *Journal of American Chemical Society*, 130, 8611-8613.
21
- 22 Lokate, A.M., Beusink, J.B., Besselink, G.A., Pruijn, G.J. & Schasfoort, R.B. (2007). *Journal of*
23 *American Chemical Society*, 129, 14013-14018.
24
- 25 Löfås, S. & Johnson, B. (1990). *Journal of the Chemical Society, Chemical Communications*
26 *article*, 1526-1528.
27
- 28 Löfås, S., Johnson, B., Edstrom, A., Hansson, A., Lindquist, G. & Müller Hillgren, R.M.S., L.
29 (1995). *Biosensors & Bioelectronics*, 10, 813-922.
30
- 31 Manera, M.G., Spadavecchia, J., Leone, A., Quaranta, F., Rella, R., Dell'atti, D., Minunni, M.,
32 Mascini, M. & Siciliano, P. (2008). *Sensors and Actuators B: Chemical*, 238, 1129-1145.
33
- 34 Manera, M.G., Rella, R., Spadavecchia, J., Moreau, J. & Canva, M. (2008a). *Journal of Optics*
35 *A: Pure and Applied Optics*, 10, 1-6.
36
- 37 Mannelli, I., Lecerf, L., Guerrouache, M., Goossens, M., Millot, M.C. & Canva, M. (2007).
38 *Biosensors and Bioelectronics*, 22, 803-809.
39
- 40 Mercey, E., Sadir, R., Maillart, E., Roget, A., Baleux, F., Lortat-Jacob, H. & Livache, T. (2008).
41 *Analytical Chemistry*, 80, 3476-3482.
42
- 43 Minunni, M., Tombelli, S., Fonti, J., Spiriti, M.M., Mascini, M., Bogani, P. & Buiatti, M. (2005).
44 *Journal of American Chemical Society*, 127, 7966-7967.
45
- 46 Minunni, M., Tombelli, S. & Mascini, M. (2007). *Analytical Letters*, 40, 1360-1367.
47
- 48 Mori, T., Inamori, K., Inoue, Y., Han, X., Yamanouchi, G., Niidome, T. & Katayama, Y. (2008).
49 *Analytical Biochemistry*, 375, 223-231.
50

- 1 Nelson, B.P., Frutos, A.G., Brockman, J.M. & Corn, R.M. (1999). *Analytical Chemistry*, 71,
2 3928.
3
- 4 Nelson, B.P., Grimsrud, T.E., Liles, M.R., Goodman, R.M. & Corn, R.M. (2001). *Analytical*
5 *Chemistry*, 73, 1-7.
6
- 7 Nelson, B.P., Liles, M.R., Frederick, K.B., Corn, R.M. & Goodman, R.M. (2002).
8 *Environmental Microbiology*, 4, 735-743.
9
- 10 Nishimura, Y., Adachi, H., Kyo, M., Murakami, S., Hattori, S. & Ajito, K. (2005). *Bioorganic &*
11 *Medicinal Chemistry Letters*, 15, 2159-2162.
12
- 13 Park, K., Ahn, J., Yi, S.Y., Kim, M. & Chung, B.H. (2008). *Biochem Biophys Res Commun*,
14 368, 684-689.
15
- 16 Pattnaik, P. (2005). *Applied Biochemistry and Biotechnology*, 126, 79-92.
17
- 18 Persson, M., Bülow, L. & Mosbach, K. (1990). *FEBS Letters*, 270, 41-44.
19
- 20 Piliarik, M., Parova, L. & Homola, J. (2008). *Biosensors and Bioelectronics*,
21
22 Quail, J.C., Rako, J.G. & Simon, H.J. (1983). *Optics Letters*, 8, 377-379.
23
- 24 Rebe Raz, S., Bremer, M.G., Giesbers, M. & Norde, W. (2008). *Biosensors and Bioelectronics*,
25 24, 552-557.
26
- 27 Ro, H.S., Jung, S.O., Kho, B.H., Hong, H.P., Lee, J.S., Shin, Y.B., Kim, M.G. & Chung, B.H.
28 (2005). *Applied and Environmental Microbiology*, 71, 1089-1092.
29
- 30 Ro, H.S., Koh, B.H., Jung, S.O., Park, H.K., Shin, Y.B., Kim, M.G. & Chung, B.H. (2006).
31 *Proteomics*, 6, 2108-2111.
32
- 33 Ross, H., Armstrong, C.G. & Cohen, P. (2002). *Biochemical Journal*, 366, 977-891.
34
- 35 Ruummele, J.A., Golden, M.S., Gao, Y., Cornelius, E.M., Anderson, M.E., Postelnicu, L. &
36 Georgiadis, R.M. (2008). *Analytical Chemistry*, 80, 4752-4756.
37
- 38 Schasfoort, R.B.M. & Tudos, A.J. (2008) *Handbook of Surface Plasmon Resonance*. RSC
39 Publishing,
40
- 41 Schroeder, H., Adler, M., Gerigk, K., Müller-Chorus, B., Gotz, F. & Niemeyer, C.M. (2009).
42 *Analytical Chemistry*, 81, 1275-1279.
43
- 44 Smith, E.A., Thomas, W.D., Kiessling, L.L. & Corn, R.M. (2003). *Journal of American*
45 *Chemical Society*, 125, 6140-6148.
46
- 47 Sola-Penna, M., dos Santos, A.C., Alves, G.G., El-Bacha, T., Faber-Barata, J., Pereira, M.F.,
48 Serejo, F.C., Da Poian, A.T. & Sorenson, M. (2002). *Journal of Biochemical and Biophysical*
49 *Methods*, 50, 129-140.
50

- 1 Tombelli, S., Minunni, M. & Mascini, M. (2007). *Biomolecular Engineering*, 24, 191-200.
2
3 Tombelli, S., Minunni, M. & Mascini, M. (2005). *Methods*, 37, 48-56.
4
5 Visser, N.F. & Heck, A.J. (2008). *Expert Review of Proteomics*, 5, 425-433.
6
7 Wakao, M., Saito, A., Ohishi, K., Kishimoto, Y., Nishimura, T., Sobel, M. & Suda, Y. (2008).
8 *Bioorganic & Medicinal Chemistry Letters*, 18, 2499-2504.
9
10 Wang, Z., Wilkop, T., Xu, D., Dong, Y., Ma, G. & Cheng, Q. (2007). *Analytical and*
11 *Bioanalytical Chemistry*, 389, 819-825.
12
13 Wark, A.W., Lee, H.J. & Corn, R.M. (2008). *Angewandte Chemie International Edition*, 47,
14 644-652.
15
16 Wark, A.W., Lee, H.J. & Corn, R.M. (2005). *Analytical Chemistry*, 77, 3904-3907.
17
18 Wassaf, D., Kuang, G., Kopacz, K., Wu, Q.L., Nguyen, Q., Toews, M., Cosic, J., Jacques, J.,
19 Wiltshire, S., Lambert, J., Pazmany, C.C., Hogan, S., Ladner, R.C., Nixon, A.E. & Sexton, D.J.
20 (2006). *Analytical Biochemistry*, 351, 241-253.
21
22 Wegner, G.J., Jin-Lee, H. & Corn, R.M. (2004) Surface Plasmon Resonance Imaging
23 Measurements of DNA, RNA, and Protein interactions to Biomolecular Arrays. In *Protein*
24 *Microarray Technology*, Wiley, pp. 107-129.
25
26 Wegner, G.J., Lee, H.J., Marriott, G. & Corn, R.M. (2003). *Analytical Chemistry*, 75, 4740-
27 4746.
28
29 Williams, A.E., Perry, M.M., Moschos, S.A., Lerner-Svensson, H.M. & Lindsay, M.A. (2008).
30 *Biochemical Society Transactions*, 36, 1211-1215.
31
32 Yeatman, E. & Ash, E.A. (1987). *Electronics Letters*, 23, 1091-1092.
33
34 Yuk, J.S., Kim, H.S., Jung, J.W., Jung, S.H., Lee, S.J., Kim, W.J., Han, J.A., Kim, Y.M. & Ha,
35 K.S. (2006). *Biosensors and Bioelectronics*, 21, 1521-1528.
36

1 Legend to Figures

2
3 Fig. 1:
4 a) Kretschmann configuration for SPRi; a high refractive index prism is in contact with the
5 detection cell and couples the incident light to the surface plasmons by evanescent waves. p-
6 polarised light is directed to the prism, on which the biomolecular probe is tethered, and a CCD
7 camera collects the output signal as variations in reflectivity.

8 b) Data are recorded as intensity variation of the reflected light at a fixed angle for each ROI
9 selected. A differential image (left) is produced in real time together with the relative
10 sensorgrams. As example here are reported two sets of signals corresponding to the interaction
11 with different chemically modified areas. During the specific interaction with the target analyte,
12 only the relative specific probe will react, leading to a local change in intensity of reflected light.
13 This translates into black/white contrast for the image. The unspecific receptor series (used as
14 negative control) will give negligible or none signal.

15 c) Sensorgrams corresponding to the interactions of the analyte with the spots on the surface.

16

17 Fig. 2

18 Immobilisation methods using chemical linkers. A self-assembled monolayer is created as the
19 foundation of the array comprising alkaneth L R O V F R Q W D n a t e l a n e, hydroxylic or
20 carboxylic functional groups. After the formation of the thiolated layer many immobilisation
21 chemistries can be performed.

22

23 Fig. 3

24 Immobilisation methods exploiting direct attachment of the probe to the gold surface of the chip
25 using thiol- and pyrrole-functionalised biomolecules.

26

27 Fig. 4

28 Signal improvement in SPRi based on mass/colorimetric approaches. The upper diagram shows
29 the DNA hybridisation step followed by addition of streptavidin and biotinylated DNA for signal
30 amplification. In the lower drawing, an aptamer array is exposed to the ligand protein (VEGF)

1 and then biotinylated antibody forms a sandwich-type assay. The SPRi signal was amplified
2 using an anti-biotin conjugated horseradish peroxidase (HRP) that in presence of a suitable
3 substrate creates a localised dark-blue precipitation reaction.

4
5 Fig. 5

6 Gold nanoparticles for SPRi signal enhancement. The upper drawing shows gold nanoparticles
7 coated with oligonucleotide sequences able to bind the free moiety of the target DNA after the
8 probe/target duplex formation. A similar approach is shown in bottom drawing, in which gold
9 nanoparticles are coated with a poly-T tail able to bind the target sequence on a suitable poly-A
10 end.

11
12 Fig. 6

13 Signal amplification by a “switch on/off” detection strategy: the SPRi signal is produced only if
14 the target sequence fully matches to the specific probe sequence. The array consists of two probe
15 types, differing in the presence or absence of a sequence specific to the SNP. The array is
16 exposed to target solution (blue bars) that contains the ligation probe DNA (orange bar) and Taq
17 DNA ligase (grey round shape). Duplexes that are formed comprise the combination of probe
18 (grey bars), target sequence (blue bar) and ligation probe DNA (orange bar) regardless of the
19 presence of the mutation (Step 1). Since ligation occurs only on fully matched duplexes (no
20 SNP), the addition of nanoparticles carrying nucleotide sequence complementary to the ligation
21 probe (Step 2) produces a SPRi signal only if target DNA does not contain the SNP.

22
23 Fig. 7

24 Diagram of the approach proposed by Goodrich and colleagues for the enhancement of SPRi
25 sensitivity. Step 1: a RNA microarray is exposed to target solution containing the enzyme RNase
26 H and the target DNA sequence; Steps 2 and 3: once the RNA/DNA heteroduplexes are formed,
27 RNase H starts to selectively destroy RNA strands in heteroduplexes; Step 4: target DNA strands
28 are released back to into solution and hybridise other free RNA probes on the surface, promoting
29 their subsequent destruction. The decrease in percent reflectivity becomes larger with time
30 until all of the available RNA probes on the surface are destroyed (Step 6).